ALK5

ALK5, also known as transforming growth factor-β type I receptor (TGFβRI/TβRI), is a serine/threonine kinase receptor that functions as a central mediator of canonical TGF-β signaling and transduces extracellular TGF-β cues into intracellular transcriptional responses through receptor-regulated signaling cascades^[1][2]. Mechanistically, ALK5 forms a receptor complex with TGF-β type II receptor and mediates downstream signaling through phosphorylation-dependent pathways, including activation of Smad proteins that regulate gene expression and cellular responses^[3][4]. Through these signaling mechanisms, ALK5 contributes to biological processes associated with extracellular matrix production, cellular proliferation, migration, and morphologic regulation, making it a widely used target in studies of fibrosis and cancer-related signaling^[3][5]. In disease and experimental models, pharmacological inhibition of ALK5 suppresses TGF-β-induced extracellular matrix production, inhibits TGF-β-mediated cellular responses, and reduces proliferation or motility in multiple cell systems^[3][5]. Compared with related activin receptor-like kinases, ALK5 belongs to the TGF-β signaling branch and is closely related to ALK4 and ALK7, whereas BMP-responsive receptors such as ALK1, ALK2, ALK3, and ALK6 exhibit distinct signaling specificities^[6]. For experimental applications, the small-molecule inhibitor SB-431542 is one of the most extensively characterized ALK5 inhibitors and selectively targets ALK5 together with ALK4 and ALK7 while sparing BMP receptor signaling and several MAP kinase pathways, providing a valuable tool for dissecting TGF-β-dependent biological mechanisms^[4][6].